一、主要会计数据和财务指标 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | -0.7300 | -0.5100 | -43.14 | -0.6000 | | 每股净资产（元） | 3.2 | 6.02 | -46.84 | 8.27 | | 每股公积金(元) | 14.91 | 14.91 | 0 | 14.63 | | 每股未分配利润(元) | -12.73 | -9.90 | -28.59 | -7.35 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 0.45 | 0.68 | -33.82 | 0.04 | | 净利润(亿元) | -2.92 | -2.06 | -41.75 | -2.41 | | 净资产收益率(%) | -20.50 | -8.24 | -148.79 | -7.07 | 数据四舍五入，查看更多财务数据>> | 名称 | 持有数量(万股) | 占总股本比 | 增减情况 | | --- ...

Financial Performance - The company's revenue for Q1 2025 was ¥44,788,452.49, representing a decrease of 33.70% compared to ¥67,555,138.51 in the same period last year[4] - The net profit attributable to shareholders was -¥291,728,135.28, worsening from -¥205,658,524.39 year-on-year[4] - The basic and diluted earnings per share were both -¥0.73, compared to -¥0.51 in the same period last year[4] - The net loss for Q1 2025 was CNY 292,457,640.37, compared to a net loss of CNY 206,210,666.06 in Q1 2024, indicating a worsening of 41.8%[27] - The company recorded a negative comprehensive income of CNY 292,498,768.44 for Q1 2025, compared to a negative comprehensive income of CNY 206,087,581.46 in Q1 2024[27] - The total comprehensive income attributable to minority shareholders for Q1 2025 was -729,505.09 RMB, compared to -552,141.67 RMB in Q1 2024, indicating a decline[29] Research and Development - Research and development (R&D) expenses totaled ¥208,545,133.67, an increase of 14.49% from ¥182,152,879.71 in the previous year[4] - R&D expenses accounted for 465.62% of revenue, up by 195.98 percentage points from 269.64% in the previous year[5] - The company continues to invest heavily in clinical trials for multiple research projects, contributing to high R&D expenses[8] - The company is focusing on differentiated innovation in R&D, achieving notable results in its pipeline[12] Clinical Trials and Product Development - The company has 16 core products in various stages, including 12 innovative drugs and 4 biosimilars, focusing on oncology and age-related diseases[11] - The innovative drug 9MW2821 has been included in the breakthrough therapy list by the National Medical Products Administration, targeting advanced urinary tract cancer[12] - Clinical trials for 9MW2821 have enrolled over 800 patients, with three key Phase III trials currently ongoing[12] - The company’s 9MW1911 drug for chronic obstructive pulmonary disease (COPD) has completed the enrollment of 80 patients in Phase Ib/IIa trials and is in the follow-up stage[14] - The company is preparing for a larger sample size Phase II clinical trial for 9MW1911, which is the first drug of its kind to enter clinical trials in China[14] - The company has received clinical trial approval for JS207, aimed at treating advanced solid tumors[12] - The clinical safety and efficacy of 9MW2821 have been validated, with significant potential in treating various cancers[12] - The company’s innovative drug 9MW3011 for treating Polycythemia Vera (PV) has completed the first patient enrollment in an open-label Ib phase clinical study, with plans for a phase II study in the US in the first half of 2025[15] - 9MW3011 is the first targeted TMPRSS6 monoclonal antibody for PV treatment globally, with 78% of patients unable to control hematocrit levels and a significant thrombotic event rate of 34-41%[15] - The company’s product 1MW5011 for osteoarthritis is in phase II clinical trials, with advantages over existing intra-articular therapies, including oral administration and better long-term treatment compliance[17] - The company’s antibody-drug conjugate 7MW3711 has received clinical trial approval for a multi-center study in advanced solid tumors, expected to start in April 2025[17] - The company’s biosimilar drug 9MW0813 has submitted a pre-NDA communication request to the National Medical Products Administration, with a formal NDA submission planned for 2025[17] Financial Position - The total assets at the end of the reporting period were ¥4,191,356,415.53, a decrease of 1.97% from ¥4,275,508,853.05 at the end of the previous year[5] - The equity attributable to shareholders decreased by 18.59% to ¥1,277,151,626.39 from ¥1,568,877,364.27 at the end of the previous year[5] - Total liabilities increased to CNY 2,928,033,610.17, up from CNY 2,719,730,804.72, representing a growth of 7.7%[24] - The company's equity attributable to shareholders decreased to CNY 1,277,151,626.39 from CNY 1,568,877,364.27, a decline of 18.6%[24] - The cash and cash equivalents decreased to CNY 80,860,527.91 from CNY 86,293,283.11, a drop of 6.0%[23] - The company reported cash and cash equivalents of approximately CNY 1.12 billion, a slight decrease from CNY 1.19 billion at the end of 2024[22] Cash Flow - The net cash flow from operating activities was -¥216,616,741.17, an improvement from -¥330,596,938.03 in the same period last year[4] - Cash inflows from operating activities in Q1 2025 totaled 59,382,060.81 RMB, down 34.4% from 90,544,176.33 RMB in Q1 2024[30] - Cash outflows from operating activities in Q1 2025 were 275,998,801.98 RMB, a decrease of 34.5% compared to 421,141,114.36 RMB in Q1 2024[30] - Cash inflows from investing activities in Q1 2025 were 32,155,778.45 RMB, down 70.2% from 107,716,644.21 RMB in Q1 2024[31] - The net cash flow from investing activities for Q1 2025 was -54,977,359.47 RMB, an improvement from -175,788,921.01 RMB in Q1 2024[31] - Cash inflows from financing activities in Q1 2025 amounted to 751,840,000.00 RMB, a decrease of 44.6% from 1,360,160,000.00 RMB in Q1 2024[31] - The net cash flow from financing activities for Q1 2025 was 181,132,528.98 RMB, down 68.9% from 584,440,756.11 RMB in Q1 2024[31] - The ending cash and cash equivalents balance for Q1 2025 was 1,136,965,756.42 RMB, compared to 1,721,702,106.25 RMB at the end of Q1 2024, indicating a decrease of 33.9%[31] Market Presence and Strategy - The company has shipped a total of 418,088 units of its product Mai Li Shu® and has established access in 1,986 hospitals across 30 provinces[19] - The company’s product Mai Wei Jian® was approved for market on March 29, 2024, with 14,320 units shipped by the end of the reporting period[19] - The company has received a drug production license from the Shanghai Municipal Drug Administration, enhancing its capabilities as a marketing authorization holder[20] - The company is actively integrating AI technology into its biopharmaceutical development, partnering with leading AI firms to improve research efficiency[19] - The company is actively expanding its market presence in oncology and respiratory diseases, with a strong emphasis on innovative therapies[12]

证券代码：688062 证券简称：迈威生物 公告编号：2025-021 迈威（上海）生物科技股份有限公司 关于对全资子公司泰康生物增资的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 增资标的名称：迈威（上海）生物科技股份有限公司（以下简称"公司" 或"迈威生物"）的全资子公司江苏泰康生物医药有限公司（以下简称"泰康 生物"）。 资金来源及增资金额：公司拟使用自有资金向泰康生物增资 40,000 万 元。 统一社会信用代码：91321291678341722J 法定代表人：刘大涛 注册资本：48,000 万元人民币 本次增资已经公司第二届董事会第十八次会议审议通过，无需提交股东 大会审议。 本次增资不构成关联交易，亦不构成《上市公司重大资产重组管理办法》 规定的重大资产重组情形，不会改变公司合并报表范围。 一、本次增资概述 泰康生物系公司的全资子公司，按照公司集团化战略部署，公司拟使用自 有资金向泰康生物增资 40,000 万元，增资完成后，泰康生物注册资本由 48,000 万元增至 88,000 万 ...

迈威生物公告，2025年第一季度营收为4478.85万元，同比下降33.70%；净亏损2.92亿元，去年同期净 亏损2.06亿元。 ...

本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 4 月 21 日 （二） 股东大会召开的地点：上海市浦东新区李冰路 576 号创想园 3 号楼 103 会议室 证券代码：688062 证券简称：迈威生物 公告编号：2025-020 迈威（上海）生物科技股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 138 | | --- | --- | | 普通股股东人数 | 138 | | 2、出席会议的股东所持有的表决权数量 | 199,591,712 | | 普通股股东所持有表决权数量 | 199,591,712 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 49.9478 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 49 ...

北京植德（上海）律师事务所 关于迈威（上海）生物科技股份有限公司 2024 年年度股东大会的 法律意见书 植德沪（会）字[2025]0005 号 关于迈威（上海）生物科技股份有限公司 2024 年年度股东大会的 法律意见书 植德沪（会）字[2025]0005 致：迈威（上海）生物科技股份有限公司（贵公司） 北京植德（上海）律师事务所（以下简称"本所"）接受贵公司的委托，指 派律师出席并见证贵公司 2024 年年度股东大会（以下简称"本次会议"）。 本所律师参加本次会议进行见证，并根据《中华人民共和国公司法》（以下 简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司股东会规则》（以下简称"《股东会规则》"）、《律师事务所从事 证券法律业务管理办法》（以下简称"《证券法律业务管理办法》"）、《律师 事务所证券法律业务执业规则（试行）》（以下简称"《证券法律业务执业规则》"） 等相关法律、行政法规、规章、规范性文件及《迈威（上海）生物科技股份有限 公司章程》（以下简称"《公司章程》"）的规定，就本次会议的召集与召开程 序、召集人资格、出席会议人员资格、会议表决程序及表决结果等事宜 ...

迈威（上海）生物科技股份有限公司 2024 年年度股东大会会议资料 2025 年 4 月 | 2024 年年度股东大会会议须知 2 | | --- | | 2024 年年度股东大会会议议程 4 | | 2024 年年度股东大会会议议案 6 | | 议案一、关于公司《2024 年年度报告》及摘要的议案 6 | | 议案二、关于公司《2025 年度财务预算报告》的议案 7 | | 附件一：2025 年度财务预算报告 8 | | 议案三、关于公司《2024 年度财务决算报告》的议案 9 | | 附件二：2024 年度财务决算报告 10 | | 议案四、关于公司 2024 年度利润分配方案的议案 13 | | 议案五、关于续聘公司 2025 年度审计机构的议案 14 | | 附件三：拟聘会计师事务所的基本情况 15 | | 议案六、关于公司《2024 年度董事会工作报告》的议案 17 | | 附件四：2024 年度董事会工作报告 18 | | 议案七、关于公司《2024 年度监事会工作报告》的议案 25 | | 附件五：2024 年度监事会工作报告 26 | | 议案八、关于公司 2025 年度董事、监事薪酬方案的议 ...

Core Viewpoint - The company, Maiwei Biotech, is facing severe financial challenges, including significant losses and cash flow issues, prompting multiple rounds of financing to sustain operations [1][2][4][5]. Financial Performance - Maiwei Biotech reported a revenue of 200 million yuan in 2024, a year-on-year increase of 56.28%, but still incurred a net loss of 1.044 billion yuan, with losses slightly narrowing by 0.9% compared to the previous year [1]. - Cumulative losses over three years reached 3.052 billion yuan, with daily cash burn averaging nearly 2.8 million yuan [2]. - The company's operating cash flow has been negative for three consecutive years, totaling a cash outflow of 2.458 billion yuan [4]. Financing Activities - The company has initiated a series of financing efforts, including a recent plan to issue up to 500 million yuan in targeted debt financing tools [1][5]. - The credit and financing limits have been increased from 2.3 billion yuan to 6.2 billion yuan over the past year [5]. Research and Development - Maiwei Biotech has invested heavily in R&D, with cumulative expenses reaching 2.378 billion yuan from 2022 to 2024, which is 6.7 times the total revenue during the same period [2]. - The company has three commercialized products but has struggled to generate significant sales, with total drug sales in 2023 amounting to only 42.09 million yuan, far below expectations [3]. Market Position and Challenges - The company aimed to replicate the success of peers like Heng Rui Medicine but has faced challenges in product sales and market penetration [3]. - The asset-liability ratio has surged from 24% at the time of listing to 63.61%, indicating increasing financial risk [4]. Management and Operational Issues - The company has experienced significant turnover in its management team, with key personnel leaving, which may impact its operational capabilities [8]. - The R&D team has been reduced by 30% from 568 members in 2022 to 403 in 2024, raising concerns about the company's innovation potential [8]. Future Outlook - Despite attempts to secure funding through various channels, the company must address low R&D efficiency and a scattered strategic focus to avoid a cycle of financing and losses [9].

Core Viewpoint - Maiwei Biotech (688062) reported a net loss exceeding 1 billion yuan for 2024, with an increasing debt-to-asset ratio surpassing 60%, prompting the company to seek financing to improve its financial position [1][4]. Financial Performance - In 2024, Maiwei Biotech achieved an operating revenue of approximately 200 million yuan, representing a year-on-year growth of 56.28% [1][2]. - The net profit attributable to shareholders was -1.044 billion yuan, slightly improved from -1.053 billion yuan in the previous year [2][3]. - Total assets decreased by 4.03% to approximately 4.276 billion yuan compared to 2023 [2]. Product and R&D Pipeline - Despite having three products on the market, the company has not yet achieved profitability and has accumulated losses [3]. - Maiwei Biotech has 16 products in various stages of development, including 12 innovative drugs and 4 biosimilars, focusing on oncology and age-related diseases [3]. - The company emphasizes the combination use of ADC, IO, and TCE as a significant development direction and plans to explore combination therapies with external products [3]. Financing and Debt Management - The company's reliance on external financing has led to a rising debt-to-asset ratio, which increased from 24% in 2022 to 63.61% in 2024 [4]. - To optimize its debt structure and reduce financial costs, Maiwei Biotech plans to issue targeted debt financing tools not exceeding 500 million yuan [4]. - The company is also planning to list in Hong Kong to meet its funding needs and enhance its international presence [4].

Group 1 - Galaxy Fund recently conducted research on 10 listed companies, including Baile Tianheng, Maiwei Bio, and Zhonghang Heavy Machinery [1][2][3] - Baile Tianheng achieved revenue of 582.27 million yuan in 2024, a year-on-year increase of 936.31%, and net profit of 370.75 million yuan, turning a profit [1] - Maiwei Bio made progress in ADC and TCE platforms, collaborating with Insilico Medicine to enhance ADC development efficiency using AI technology [2] - Zhonghang Heavy Machinery's 2025 revenue target is 11.5 billion yuan, with a profit target of 1.3 billion yuan, and expects stable demand in Q1 2024 [3] Group 2 - Olin Bio is advancing its recombinant pneumococcal vaccine phase III clinical trial, with over 5,600 cases enrolled [3] - Haizheng Pharmaceutical anticipates growth in raw materials, formulations, and e-commerce by 2025, with a focus on reducing costs and enhancing product competitiveness [4] - Semir Apparel reported total revenue of 14.63 billion yuan in 2024, a 7.06% increase, with children's apparel accounting for 70.21% of revenue [5] Group 3 - Huayang Group's automotive electronics business is optimizing customer structure, with an increase in major clients and new projects [6] - Huafeng Chemical's gross margin declined due to lower margins in basic chemical products, but it is optimistic about future demand for spandex [7] - Ruifeng New Materials is addressing increased accounts receivable due to new and existing customer sales, while planning to enhance its global market share through innovation [8] Group 4 - Weixing Co. achieved significant growth in its button and zipper business, with zipper revenue increasing by 16% and button revenue by 22% in 2024 [9] - The company aims for a revenue target of 5 billion yuan in 2025, focusing on becoming a global and innovative fashion accessory leader [9] - The company is also expanding its production capacity and enhancing its competitive advantages through product diversity and innovation [9]